{"id":"moderate-dose-cannabidiol","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Changes in appetite"},{"rate":null,"effect":"Hepatic enzyme elevation"},{"rate":null,"effect":"Drug-drug interactions via CYP3A4/CYP2C19"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cannabidiol (CBD) is a non-intoxicating cannabinoid that acts as a negative allosteric modulator of CB1 and CB2 receptors, while also interacting with serotonin receptors (5-HT1A), vanilloid receptors (TRPV1), and other targets. These interactions produce anti-inflammatory, anticonvulsant, and anxiolytic effects without the psychoactive properties of THC. The moderate-dose formulation is designed to optimize therapeutic efficacy while minimizing adverse effects.","oneSentence":"Cannabidiol modulates endocannabinoid signaling and multiple receptor pathways to produce anti-inflammatory, anxiolytic, and neuroprotective effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:59.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seizure disorders (epilepsy)"},{"name":"Anxiety disorders"},{"name":"Chronic pain"},{"name":"Inflammation-related conditions"}]},"trialDetails":[{"nctId":"NCT06533657","phase":"PHASE2","title":"Unique Treatment of Oncology Pain in Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ZYUS Life Sciences Inc.","startDate":"2025-06-12","conditions":"Cancer Pain","enrollment":20},{"nctId":"NCT07123467","phase":"PHASE3","title":"Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder","status":"RECRUITING","sponsor":"Wayne State University","startDate":"2025-11-03","conditions":"Generalized Anxiety Disorder (GAD), Anxiety Disorders","enrollment":90},{"nctId":"NCT05632627","phase":"PHASE2","title":"Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2023-04-11","conditions":"Brain Injuries, Traumatic","enrollment":43},{"nctId":"NCT05299944","phase":"PHASE2","title":"Reducing Pain and Opioid Use With CBD","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2022-03-08","conditions":"Opioid Use Disorder","enrollment":126},{"nctId":"NCT06448923","phase":"PHASE2","title":"Cannabidiol After Multi-Trauma for Pain and Opioid Therapy","status":"RECRUITING","sponsor":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","startDate":"2025-06-01","conditions":"Fracture","enrollment":225},{"nctId":"NCT04873453","phase":"PHASE2","title":"CBD for the Treatment of Alcohol Use Disorder","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2021-08-30","conditions":"Alcohol Use Disorder","enrollment":45},{"nctId":"NCT05822362","phase":"PHASE2","title":"CBD for Individuals at Risk for Alzheimer's Disease","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-01-19","conditions":"Mild Cognitive Impairment","enrollment":236},{"nctId":"NCT05613608","phase":"PHASE2, PHASE3","title":"Alcohol Use Disorder and Cannabidiol","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-04-30","conditions":"Alcohol Use Disorder","enrollment":180},{"nctId":"NCT05044936","phase":"EARLY_PHASE1","title":"Topical Cannabidiol Cream and Post-exercise Recovery","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2023-05-15","conditions":"Muscle Damage","enrollment":""},{"nctId":"NCT01887301","phase":"PHASE1","title":"Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2013-07","conditions":"Hepatic Impairment","enrollment":32},{"nctId":"NCT03944447","phase":"PHASE2","title":"Outcomes Mandate National Integration With Cannabis as Medicine","status":"UNKNOWN","sponsor":"OMNI Medical Services, LLC","startDate":"2018-12-01","conditions":"Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury","enrollment":200000},{"nctId":"NCT03573518","phase":"PHASE2","title":"Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris","status":"COMPLETED","sponsor":"Botanix Pharmaceuticals","startDate":"2018-06-26","conditions":"Acne Vulgaris","enrollment":368},{"nctId":"NCT04467918","phase":"PHASE2, PHASE3","title":"CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2020-07-06","conditions":"SARS-CoV2","enrollment":100},{"nctId":"NCT04193631","phase":"PHASE1","title":"Low Dose of Cannabidiol (CBD) to Treat Mild to Moderate Musculoskeletal Pain","status":"COMPLETED","sponsor":"Pure Green","startDate":"2019-12-07","conditions":"Musculoskeletal Pain","enrollment":16},{"nctId":"NCT01562314","phase":"PHASE2","title":"A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)","status":"COMPLETED","sponsor":"GW Research Ltd","startDate":"2012-05-09","conditions":"Ulcerative Colitis","enrollment":60},{"nctId":"NCT01596075","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2012-07","conditions":"Graft Versus Host Disease","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["EPIDIOLEX®"],"phase":"phase_3","status":"active","brandName":"Moderate-Dose Cannabidiol","genericName":"Moderate-Dose Cannabidiol","companyName":"Wayne State University","companyId":"wayne-state-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cannabidiol modulates endocannabinoid signaling and multiple receptor pathways to produce anti-inflammatory, anxiolytic, and neuroprotective effects. Used for Seizure disorders (epilepsy), Anxiety disorders, Chronic pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}